FdaApplication
NDA 021752
Identifiers
- fda_app_no: NDA021752
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2004-08-02 |
Revenue by product
TRUVADA
| Period | Revenue |
|---|---|
| Q4 2023 | $17.0M* |
| Q3 2023 | $22.0M* |
| Q4 2022 | $45.0M* |
| Q3 2022 | $30.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRUVADA | EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | 133MG;200MG | TABLET;ORAL |
| TRUVADA | EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | 167MG;250MG | TABLET;ORAL |
| TRUVADA | EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | 200MG;300MG | TABLET;ORAL |
| TRUVADA | EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | 100MG;150MG | TABLET;ORAL |
4 products